The Development of tablet formulation of Artocarpus champeden Stembark extract as antimalarial drug

Abstract

Parasite resistance to antimalarial drug, chloroquine and sulfadoxin-pirimetamin, still e major problem in malaria control worldwide, thereforc, the cffort in developing a new targct of antimalarial drug become a high priority. Our preliminary test revealed that fuom A. chanpeden exhibiedt potent antimalarial activities againts P. lalciparum in vitro brghci in vivo. Several isolaEd compounds from this plant exhibited antimalarial activity drc isotated compound identified as hetcroflavon C, a prenylated flavooe, have a higher activity than chloroquine. Therefore, it is potential to be developed as antimalarial rcscarch was conducted to develop tablet formulation of ethanol extract of A. stcmbark (EEAC). The formula that composed: EEAC 150 mg, lactose 140 mg, cabarnilum 46 mg, avicel PH l0l 79o, primogcl 57o, and Mg stcarat 1% was the selected Th€ tablet hardness o[ the formula has span betwccn 9.0-12.27 kP and the averagc is , thc disintegration time of formula 12 minutcs 4? seconds. A standard fiays test oll P. infected mice was used to evaluated in vrv, antimalarial activity of the tablet. This rlvcalcd that EEAC tablet has antimalarial activity against parasite P. berghei in vivo. ration ofEEAC tablet at a dose of 10 mg/kg body weight multiple dose (twice a day) thc parasite growth better than 100 mg/kg body weight single dose (once a day) activity of tablet in multiple dose pcr oral shqwed inhibition of parasite growth of while at single dose per oral showed inhibition of parasite growth of 83.32